Financing channel feed – Endpoints News

Financing channel feed

Revolution Medicines looks to raise $230M in new public offering

3 years ago

With a fresh $100M in hand, one RNA startup is moving to the clinic, finding partners and building a new lab — all at once

3 years ago

Looking to climb out of bear market and FDA hurdles, Summit offers up $100M worth of stock

3 years ago

In bid to avoid immunotherapy toxicities, Cartography charts a course toward modality-agnostic drugs

3 years ago

Immunocore is the latest to nab a private placement, securing $140M to pursue more TCR R&D

3 years ago

Samsung’s CDMO arm commits to $324M land purchase for a second bio campus

3 years ago

Oxford Science Enterprises collects $300M to offer spinouts 'scale-up capital'

3 years ago

Exclusive: After Covid pivot, biotech nabs funds to be first in the clinic with a non-hormonal contraceptive for men

3 years ago

Protein therapeutics biotech using 'protein barcodes' in drug development secures new financing — led by Jeff Huber

3 years ago

Novo Nordisk nabs priority review voucher for $110M from Marinus as the biotech preps first drug launch

3 years ago

Pfizer dips its toe into fibrosis and organ regeneration, leading raise extension for Belgium's Agomab

3 years ago

Quiet neurodegenerative disease startup secures $100M from unnamed investors

3 years ago

Flagship unwraps new AI biotech that looks to predict variants before they’re here

3 years ago

Big Pharma vet teams with former Doudna pupil to launch new epigenome startup

3 years ago

Can positive but exploratory data entice investors to $150M raise in a bear market? Pliant will find out

3 years ago

Struggling biotech sells its API manufacturing arm to narrow its focus

3 years ago

Updated: Different way to go after KRAS mutant tumors? Novo-backed biotech nabs $50M to wrap early studies

3 years ago

VC dollars keep rolling in as Qiming ties a ribbon on $2.5B Fund VIII

3 years ago

Athersys’ woes continue as Aspire Capital axes its relationship with the biotech

3 years ago

Despite plenty of bears and little investor appetite, three biotechs beef up 2022's private placement lows

3 years ago

Pushing mRNA therapeutics for cancer, Cambridge startup nabs Series A to explore next-gen approach

3 years ago

Boehringer Ingelheim, Evotec band with diagnostics player to tackle 'superbugs' through joint venture

3 years ago

With Lilly's backing, a CRO with roots in China bags $150M round to fuel global growth

3 years ago

Bruised Syros scores $130M PIPE from marquee group — while grabbing $60M cash from all-stock merger

3 years ago

First page Previous page 50 51 525354 55 56 Next page Last page